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1 
SUMMARY 
 
Anaplastic Large Cell Lymphoma (ALCL) represents a distinct subset of aggressive T-cell 
non-Hodgkin lymphoma (NHL) accounting for about 3% of adult NHL and 10 to 15% of 
childhood lymphomas. In the vast majority of the cases, ALCL is associated to 
chromosomal translocations, the most frequent being the t(2;5)(p23;q35), involving the 
Anaplastic Lymphoma Kinase (ALK) gene, which lead to aberrant NPM-ALK protein 
expression and kinase activity. It has been extensively demonstrated that aberrant  
NPM-ALK expression contributes to the pathogenesis of ALK-positive ALCL, as it causes 
cell transformation through activation of several biological pathways related to cell 
proliferation, cell-cycle control and apoptosis. Although ALK-positive ALCL have a rather 
benign prognosis when treated with standard chemotherapy, the failure rate at two 
years is almost 30% for most of these regimens. Notably, most of relapses occur within 
the first year from the start of therapy, and long-term survival for relapsed disease is 
less than 50%. Aberrant ALK activity is one of the major oncogenic events not only in 
ALK-positive ALCL, but also in neuroblastoma, non-small cell lung cancer (NSCLC) and 
inflammatory myofibroblastic tumour (IMT) bearing ALK activating 
mutations/rearrangements, and the inhibition of ALK kinase activity was proven to 
substantially reduce cancer cell proliferation and invasiveness both in vitro and in vivo. 
Successful clinical experience with crizotinib further support the concept of ALK-specific 
inhibition as a valuable treatment strategy in ALK-positive ALCL, as well as in other  
ALK-addicted tumours. However, similarly to other inhibitors selectively targeting 
oncogenic kinases, data on relapse to crizotinib due to newly acquired secondary 
mutations were reported. In this context, although a robust clinical response of ALCL 
patients to an ALK inhibitor is expected, some of those patients are also anticipated to 
develop resistance, making the knowledge of NPM-ALK kinase domain (KD) mutational 
status a valuable and mandatory information to the rational design of ALK-targeted 
therapies.  
To detect somatic tumour mutations with potential utility for predicting treatment 
response in ALK-positive ALCL patients, we performed ultra-deep sequencing analysis on 
ALK exons 22-25, corresponding to the entire KD coding region, in 37 ALCL pediatric 
patients. Two low frequent point mutations were identified in two distinct cases, 
corresponding to the R1275Q and R1231Q amino acid changes. The R1275Q mutation 
has been already reported as one of the most frequent activating mutations in 
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neuroblastoma, while the R1231Q amino acid substitution represents a novel ALK point 
mutation, which to our knowledge has never been reported neither in ALK receptor nor 
in other ALK-translocated kinases. The molecular implications of R1275Q  and R1231Q 
point substitutions on NPM-ALK function and sensitivity to ALK-specific inhibition are 
still under our investigation. In addition to point mutation, oncokinase alternative 
spliced transcripts have been previously reported in patients with Bcr-Abl positive 
chronic myeloid leukemia and  more recently ALK receptor isoforms were described in 
neuroblastoma. To our knowledge, however, NPM-ALK alternative splicing events have 
never been described. For the first time, we identified and characterized 9 NPM-ALK 
INDEL mutations, resulting from KD whole exons skipping or alternative canonical 
splicing sites recognition. To investigate the effect of INDEL mutations on the structure 
and activity of NPM-ALK, we performed molecular homology modelling and in vitro 
functional analysis. While all these mutants were shown to be kinase dead, we 
demonstrated that, when coespressed with wild-type NPM-ALK, these INDELs do 
interact with wild-type monomers and are likely to inhibit ALK kinase activity and 
increase sensitivity to treatment with crizotinib. This work demonstrates that NPM-ALK 
KD point mutations are extremely rare in newly diagnosed ALCL patients, but positive 
selection of mutated cells could not be excluded in case of an ALK-targeting therapy. 
Conversely, our results suggest that alternative splicing in NPM-ALK may represent a 
common event. A clear correlation between the presence of these variants and outcome 
could not be detected, possibly because of the restricted cohort of patients analyzed. 
However, we hypothesize that a significant impact of these mutations could be observed 
if an ALK-specific treatment is used. Patients bearing a consistent level of inactive NPM-
ALK are therefore expected to respond differently to ALK kinase inhibitors; whether such 
a response will be increased or decreased, it remains to be elucidated. 
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RIASSUNTO 
 
Il linfoma anaplastico a grandi cellule (ALCL) è un sottotipo di linfoma non-Hodgkin (LNH) 
aggressivo prevalentemente a fenotipo T e rappresenta circa il 3%  dei LNH dell’adulto e 
il 10-15% dei linfomi pediatrici. Nella maggioranza dei casi, l’ALCL è associato alla 
presenza di traslocazioni cromosomiche che coinvolgono il gene della chinasi ALK 
(Anaplastic Lymphoma Kinase), la più frequente delle quali è la t(2;5)(p23;q35), che 
determina l’espressione aberrante della chinasi di fusione NPM-ALK, costitutivamente 
attiva. È stato ampiamente dimostrato che l’espressione aberrante di NPM-ALK 
contribuisce alla patogenesi dell’ALCL, esercitando la sua attività trasformante mediante 
l’attivazione di numerosi vie di trasduzione del segnale connesse alla proliferazione, al 
controllo del ciclo cellulare e all’apoptosi. Sebbene gli ALCL che esprimono ALK siano 
caratterizzati da una prognosi piuttosto favorevole, quando trattati secondo i protocolli 
terapeutici standard, la percentuale di fallimento di questo tipo di terapie si attesta 
comunque intorno al 30%. Inoltre, la maggior parte delle recidive si verifica entro un 
anno dall’inizio del trattamento e la sopravvivenza dei pazienti recidivati non raggiunge 
il 50%. La deregolazione di ALK rappresenta uno degli eventi oncogenici più importanti 
non soltanto nel ALCL, ma anche nel neuroblastoma, nel tumore a piccole cellule del 
polmone (NSCLC) e nel tumore miofibroblastico infiammatorio (IMT) che presentano 
mutazioni o riarrangiamenti del gene ALK. Studi in vitro ed in vivo hanno dimostrato che 
l’inibizione dell’attività chinasica di ALK riduce in modo significativo la proliferazione e 
l’invasività delle cellule tumorali. Inoltre, l’inibitore di ALK crizotinib si è dimostrato 
molto efficace per il trattamento di pazienti affetti da NSCLC, ad ulteriore dimostrazione 
che l’inibizione dell’attività catalitica di questa proteina potrebbe rappresentare una 
strategia terapeutica promettente anche nell’ALCL ALK-positivo, così come in altri 
tumori associati ad espressione aberrante di ALK. Tuttavia, analogamente a quanto è 
stato osservato con altri inibitori di tirosin chinasi oncogene, alcuni pazienti in corso di 
trattamento con crizotinib sono recidivati in seguito all’insorgenza di mutazioni a carico 
della chinasi bersaglio. In questo contesto, sebbene una terapia di questo tipo possa 
essere estremamente efficace per il trattamento dell’ALCL, è necessario tenere presente 
che alcuni pazienti potrebbero sviluppare resistenza. Risulta quindi di fondamentale 
importanza conoscere lo stato mutazionale del dominio chinasico di NPM-ALK per poter 
pianificare una strategia terapeutica il più possibile efficace. Allo scopo di identificare 
mutazioni somatiche di NPM-ALK potenzialmente associate alla risposta al trattamento 
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in pazienti con ALCL ALK-positivo, abbiamo sequenziato gli esoni 22-25 di NPM-ALK, 
corrispondenti all’intero dominio chinasico, in 37 pazienti con ALCL pediatrico, 
utilizzando un approccio di Next-Generation sequencing. In due pazienti distinti abbiamo 
identificato due mutazioni puntiformi a bassa frequenza, corrispondenti alle sostituzioni 
aminoacidiche R1275Q e R1231Q. La prima mutazione era già stata riportata nel 
neuroblastoma tra le più frequenti mutazioni attivanti, mentre la mutazione R1231Q 
non era nota né per ALK recettore, né in tumori in cui ALK è traslocato. Le implicazioni 
molecolari di queste mutazioni sull’attività di NPM-ALK e sulla sua sensibilità al 
trattamento con inibitori specifici sono oggetto di ulteriori studi in corso. Oltre alle 
mutazioni puntiformi, la presenza di trascritti derivanti da fenomeni di splicing 
alternativo è un fenomeno già noto per altre protein chinasi di fusione, come Bcr-Abl 
nella leucemia mieloide cronica, ma anche in ALK in pazienti affetti da neuroblastoma. 
Sulla base delle nostre conoscenze, tali fenomeni, tuttavia, non sono mai stati descritti 
per NPM-ALK. Per la prima volta, abbiamo identificato e caratterizzato 9 mutazioni 
INDEL di NPM-ALK, associate alla perdita di interi esoni o al riconoscimento di siti di 
splicing canonici alternativi. Allo scopo di comprendere quali potessero essere gli effetti 
di queste mutazioni sull’attività di NPM-ALK, abbiamo condotto delle analisi di  
molecular homology modelling e studi funzionali in vitro. Sebbene tutti questi mutanti 
siano risultati inattivi, abbiamo dimostrato che se vengono coespressi assieme alla loro 
controparte funzionale sono in grado di formare dei complessi con essa, riducendone 
l’attività catalitica e aumentando la sensibilità della chinasi al trattamento con crizotinib.  
Questo lavoro di tesi dimostra che mutazioni puntiformi del dominio chinasico di  
NPM-ALK sono piuttosto rare nei pazienti con ALCL prima dell’inizio della terapia, anche 
se una selezione positiva delle cellule con la mutazione potrebbe verificarsi nel caso in 
cui venisse utilizzato un trattamento a base di inibitori specifici di ALK. Al contrario, 
abbiamo dimostrato che gli eventi di splicing alternativo di NPM-ALK sono 
maggiormente frequenti, anche se non è stato possibile dimostrare una correlazione tra 
la presenza di queste varianti e il decorso della malattia, probabilmente a causa della 
bassa numerosità della nostra casistica. Tuttavia, riteniamo che queste mutazioni 
potrebbero avere un impatto significativo nel caso in cui i pazienti venissero trattati con 
inibitori specifici di ALK.  In particolare, pazienti che esprimono livelli rilevanti di 
isoforme inattive di NPM-ALK potrebbero rispondere diversamente al trattamento. 
Resta da stabilire se questa differenza possa tradursi in una maggiore o minore efficacia 
di una terapia anti-ALK in questi pazienti. 
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1. INTRODUCTION 
 
1.1 CLINICAL AND BIOLOGICAL CHARACTERIZATION OF ALCL 
 
Anaplastic Large Cell Lymphoma (ALCL) was first described by Stein et al. in 1985 [1]. It 
represents a distinct subset of aggressive T-cell non-Hodgkin lymphoma (NHL), CD30-
positive, accounting for about 3% of adult NHL and 10 to 15% of childhood lymphomas 
[2]. 
In the vast majority of the cases, ALCL is associated to chromosomal translocations 
involving the Anaplastic Lymphoma Kinase (ALK) gene, which lead to aberrant ALK 
protein expression and kinase activity (ALK-positive ALCL). The remaining cases, sharing 
similar morphologic and phenotypic features, but lacking the ALK rearrangement and 
expression (ALK-negative ALCL), are considered as a separate category [2]. 
Based on histological characteristics, ALCL are classified  as “common” type when 
composed of large, pleomorphic, atypical tumour cells with an abundant grey-blue 
cytoplasm and large  kidney-shaped nucleus, “small cell” variant when represented by a 
predominant population of medium and small cells with clear cytoplasm and irregular 
nuclei, and “lymphohistiocytic” when large numbers of histiocytes are mixed with the 
tumour cells. Other rarer types are the “giant cell-rich” subtype, with a large number of 
the tumour cells containing more than one nucleus, and the “sarcomatoid”  subtype, 
which mimics soft-tissue tumours [3]. 
ALCL has been clinically subdivided into a primary form (de novo) and a secondary form 
(anaplastic transformation from another lymphoma), and among primary ALCLs, 
systemic and cutaneous subtypes can be distinguished [4]. Primary systemic ALCL is the 
most frequent category, accounting for 2% to 8% of NHL in adults and approximatevely 
20-30% of large cell lymphoma in children [5, 6]. ALK-positive ALCL mostly occurs in 
young male adults (<30 yrs; male/female ratio 6.5), and frequently presents as an 
aggressive stage III or IV disease, usually associated to systemic symptoms and 
extranodal involvement (skin, bone, soft tissue, lung and liver). In contrast, almost 
invariably, ALK-negative ALCL is a primary cutaneous tumour, which accounts for 
approximately 9% of cutaneous lymphomas, and has a lower incidence of stage III/IV 
disease and extranodal involvement. ALK-negative ALCL affects older patients, and in 
almost 25% of the cases a partial or complete spontaneous regression is observed [7]. 
Several independent studies demonstrated a remarkably different prognosis between 
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ALK-positive and ALK-negative ALCL, with the former showing a far better survival rate 
(70-80%) than the latter one (15-45%) [8-10]. 
Approximatively 85% of ALK-positive ALCL are associated to the t(2;5)(p23;q35) 
chromosomal translocation, in which the ALK gene located at 2p23 juxtaposes to the 
NPM1 housekeeping gene at 5q35 [11], leading to a novel fusion gene, NPM-ALK, that 
encodes a constitutively active oncogenic tyrosine kinase (NPM-ALK). In the remaining 
cases, cytoplasmic-restricted expression of truncated ALK is determined by alternative 
genetic abnormalities that result in the expression of variant ALK fusion proteins, such as 
TPM3-ALK (t(1;2)(q25;p23)), TFG-ALK (t(2;3)(p23;q21)), CLTCL-ALK (t(2;22)(p23;q21)) and 
ATIC-ALK (inv(2)(p23q35)) [12-14] (Figure 1). 
 
1.2 STRUCTURE AND PATHOGENIC ROLE OF NPM-ALK 
 
The NPM-ALK fusion protein contains the N-terminal domain of NPM (aa 1-118) and the 
entire cytoplasmic region of ALK kinase (aa 119-680) (Figure 2). NPM1 is a protein of 23 
kDa that shuttles continuously between the cytoplasm and the nucleus, and plays 
multiple roles inside the cell (ribosome biogenesis, regulation of cell division, 
transcription and DNA repair) [15]. ALK, in contrast, is a receptor tyrosine kinase (RTK) of 
200 kDa (1620 aa) which contains an extracellular ligand-binding domain, a  
transmembrane-spanning domain and a cytoplasmatic catalytic region, and regulates 
important cellular functions upon ligand-induced dimerization, through phosphorylation 
and activation of several downstream target molecules. ALK belongs to the insulin 
receptor (IR) superfamily of receptor tyrosine kinases (RTKs) [16, 17] and its postnatal 
expression is restricted to few scattered cells in the nervous system [18]. The 1030 aa 
extracellular region contains 26 hydrophobic aa at its N-terminus, comprising a signal 
peptide sequence, and the binding site for two putative ligands, Pleiotrophin (PTN) and 
Midkine (MK) [19, 20]. The extracellular region also possesses several N-glycosylation 
consensus sites (Asn-X-Ser/Thr), 26 cysteine residues, an LDL-A domain, a MAM domain 
and a glycine-rich region. Next to this, a 28-aa transmembrane domain is joined to a 64-
aa juxtamembrane region, which contains a binding site for phosphotyrosine-dependent 
interaction with the insulin receptor substrate-1 (IRS-1) and precedes the intracellular 
catalytic domain and activation loop (Figure 3A, PTK). By analogy with other RTKs, 
tyrosine residues 1278, 1282 and 1283 in the activation loop  of ALK represent major 
autophosphorylation sites during kinase activation, occluding access to ATP when non 
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phosphorylated, while favouring nucleotide binding  when phosphorylated [21] (Figure 
3B). 
 
 
Figure 1 Features of the various ALK fusion proteins occurring in ALK-positive ALCL.  
§Tirosine Kinase Domain. (Stein et al., 2000) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2 Schematic representation of NPM-ALK fusion protein. 
 
 
The function of full-length ALK receptor is still poorly characterized, though PTN and MK 
have been proposed as putative ligands of ALK in mammals, and associated to ALK 
activity during neuron development and neurodegenerative diseases [19, 20]. However, 
a recent model has proposed that phosphorylation of ALK occurs through a PTN-
dependent inactivation of the receptor protein tyrosine phosphatase Z1, rather than a 
direct interaction of PTN with ALK [22], as suggested by the observation that ALK is not 
phosphorylated by PTN when phosphatase Z1 lacks or has been inactivated [23-26] 
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Conversely, the presence of an oligomerization domain in the fused gene partners of 
ALK truncated variants promotes ligand-independent dimerization of this oncogenic 
kinase, and allows fusion proteins self-phosphorylation and activation in tumour cells 
[27]. 
Indeed, aberrant NPM-ALK expression contributes to the pathogenesis of ALK-positive 
ALCL, as it causes cell transformation through activation of several biological pathways 
related to cell proliferation, cell-cycle control and apoptosis [28-31]. Consistent with 
these findings, NPM-ALK has been shown to affect growth, adhesion and migration of 
various cell types, which frequently display an enhanced motility and invasiveness due 
to ALK-dependent dysregulation of proteins controlling both the intracellular plasticity 
and the extracellular microenvironment. To do so, NPM-ALK binds to and activates a 
host of important cellular signalling molecules, including several with mitogenic and 
anti-apoptotic activities  (RAS, ERK1/2, AKT, STAT3 and JUNB) [32-38] 
 
 
 
 
    A                                                B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 (A) Domain structure of human ALK:  the N-terminal region comprises two MAM 
domains (aa 264-427 and 480-626), one LDLa domain (aa 453-471) and a glycin rich (G-rich) 
region (aa 816-940). A transmembrane(TM)-spanning segment connects the extracellular 
region with the protein tyrosine kinase (PTK) domain in the intracellular region (aa 1116-1383). 
Adapted from Palmer et al., 2009. 
(B) A representation of the apo crystal structure of ALK shown in orthogonal orientation. 
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1.3 ALK AS A THERAPEUTIC TARGET 
 
Similar to other T-cell lymphomas, the relative rarity of ALCL has limited the number of 
large prospective clinical trials to help optimize treatment, which remains, thus far, 
dependent on the use of combined intensive chemotherapy. Most European pediatric 
oncology groups use short-pulse chemotherapy regimes (high-dose methotrexate, 
cyclophospamide, vincristine, doxorubicine and corticosteroids) of 4-6 months duration 
to cure ALCL, and the failure rate at two years is almost 30% for most of these regimens. 
Notably, most of relapses (60%) occur within the first year from the start of therapy, and 
long-term survival for relapsed disease is less than 50% [39]. Therefore, although  
ALK-positive ALCL has a good prognosis compared to other childhood cancers, there is a 
continuous need for new therapeutic agents, particularly for relapsed cases. 
Genetic aberrations of ALK are recurrent in several tumour types, such as 
neuroblastoma [40-43], non-small cell lung cancer (NSCLC) [44-47] and inflammatory 
myofibroblastic tumour (IMT) [48], and compelling preclinical data indicate that tumours 
harbouring gene amplification, translocations, or activating point mutations are partially 
or fully dependent upon ALK kinase activity for proliferation and survival [43, 44, 49]. 
Consistently, the inhibition of ALK catalytic activity yields potent anti-tumour efficacy in 
vitro, thus providing a sound rationale for clinical development of ALK small-molecule 
inhibitors (Figure 4) [38, 50-52]. 
Proof of concept for this approach has been provided by clinical studies using Pfizer  
PF-2341066 inhibitor, also known as crizotinib, (ClinicalTrials.gov #NCT00585195), as ALK 
tyrosine kinase inhibitor (TKI), in refractory, heavily pre-treated NSCLC patients 
harbouring the EML4-ALK rearrangement. Among NSCLC patients, crizotinib was well 
tolerated, had rapid, durable response and correlated with improved survival [53, 54]. 
Consistent with these results, two recent case reports showed remarkable and brisk 
crizotinib activity in relapsed and refractory NPM-ALK positive ALCL as well [55], 
supporting the strong preclinical rationale of ALK inhibition in this type of tumour and in 
those others bearing ALK mutations/rearrangements. 
However, data on acquired resistance to crizotinib due to secondary mutations in the 
ALK kinase domain (KD) have been also reported [56, 57],  reflecting previous clinical 
experience with other TKIs. In this context, a wealth of clinical data demonstrate that 
resistance to drug inhibitory activity, like that observed for EGFR, c-Kit or Bcr–Abl 
oncogenic kinases, is often linked to secondary mutations in the KD, either when 
acquired de novo or resulting from selection of pre-existing, sub-dominant neoplastic 
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clones  [58-61]. Of note, dominant mutations at relapse can be detected before the 
onset of treatment as well, suggesting that drug resistance may be predicted before 
treatment starts (intrinsic resistance) and risk of failures reduced. However, mutation 
frequency at diagnosis is often below the level of detectability of direct Sanger 
sequencing, requiring more sensitive methods for detection [62-64]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 Chemical structures of some ALK inhibitors. 
 
 
1.4 ULTRA-DEEP TARGETED SEQUENCING FOR LOW PREVALENCE MUTATIONS 
DETECTION IN CANCER 
 
Sanger sequencing [65] has long been regarded as the gold standard for mutation 
detection since prior knowledge of mutations is not required and assay development is 
limited only by sequencing primer design and read length. This approach, however, is 
unreliable for detecting variants that account a small proportion (<20%) of the total 
population of genomes in a sample [66], as it generates only an average sequence of the 
PCR product. In addition, the analysis of samples with rarer heterogeneous insertion-
deletion mutations remains challenging, since minor variant detection methods that rely 
on subcloning of PCR products, in conjunction with conventional sequencing, are limited 
by bacterial cloning artefacts and time constraints. On the other hand, nonsequencing-
pyrazolo[3,4-c]isoquinoline thiazoles 
NVP-TAE684 PF-2341066 (crizotinib) 
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based assays for minor variant detection such allele-specific PCR or probe-based 
methods [67] generally offer high sensitivity, but prior knowledge of the mutation of 
interest is required and linkage of the identified mutations is not possible. By contrast, 
within the last few years, massive parallel next-generation sequencing (NGS) technology 
has greatly enhanced the scope and the speed of genomic cancer research, making the 
detection of rare mutational events precise and possible in any tumour or normal tissue. 
The power of the new sequencing technologies and their utility for variant detection 
derive from the ability to sequence single molecules in massive amounts and give the 
frequency of a each single variant in a population of DNA molecules. In this process, 
each of the single molecules of an amplicon is clonally amplified and individually 
sequenced, allowing for the identification of rare variants over the whole read length. At 
present, the 454 pyrosequencing technology achieves the longest read lengths (400–500 
bp reads) and enables the ultra-deep sequencing (UDS) of hundreds of thousands of 
molecules at high coverage [68]. The combination of high coverage and long read length 
has made the 454 pyrosequencing a promising tool for sensitive and quantitative 
detection of genomic variants, with potential applications in various clinically relevant 
research areas, including oncology and human genetics.  
The number of somatic tumour mutations with potential utility for predicting treatment 
response is rapidly growing due to increasing numbers of targeted therapies. However, 
tumour samples can be heterogeneous due to invasion into stroma, infiltration by 
immune cells, and clonal evolution. Technological advances in DNA deep sequencing 
clearly offer an important solution to the problem of analyzing heterogeneous samples. 
One of the first studies on this field by Thomas et al. [69] reported the presence of low-
abundance EGFR mutations in a relapsed lung adenocarcinoma specimen with low 
tumour content, for which conventional Sanger sequencing was not informative. 
Picotiter plate sequencing revealed the presence of a deletion mutation of 18 nt in exon 
19 of EGFR at frequency of approximatively 3%, and a nucleotide substitution encoding 
the T790M mutation in exon 20 at a frequency of 2%, the latter one known to be 
associated with clinical resistance to EGFR inhibitors.  The same 18 nt deletion was 
detected in a pretreatment sample in which tumour cells were exceptionally rare at a 
frequency of approximatively 0.3%, but no T790M mutation was revealed, consistently 
with the original erlotinib sensitivity and subsequent relapse. More recently, Choi et al. 
analyzed ALK kinase domain mutational status with a similar approach in a relapsed case 
of EML4-ALK-positive NSCLC, treated with crizotinib [56].  Two de novo point mutations 
were detected at frequencies of 41.8% and 14%, corresponding to the amino acid 
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changes C1156Y and L1196M, respectively. Ectopic expression of both mutant forms in 
BA/F3 cells determined a markedly reduced sensitivity to multiple ALK inhibitors, 
compared to cells expressing wild-type EML4-ALK, thus suggesting an association 
between these resistance mutations and patient relapse during clinical treatment with 
crizotinib. 
In a more recent study on EGFR exon 19 deletions in NSCLC, UDS highlighted the 
presence of subpopulations of DNA molecules carrying EGFR deletions different from 
the main one in 43% of analyzed tumour samples, with a frequency between 0.1% and 
17% [70]. These findings were correlated to a marked instability of a region in exon 19 of 
EGFR, to a different protein antigenicity and dismal outcome. 
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2. OBJECTIVES 
 
Tyrosine kinase inhibitors are extremely effective drugs for the treatment of tumours 
associated to the expression and activity of mutated, oncogenic protein tyrosine kinases. 
However, clinical studies thus far indicate that a significant portion of patients acquire clinical 
resistance after achieving initial response, in most cases due to  selection of cancer cells with 
mutations in the targeted PTK. 
Based on these observations, we hypothesize that a good clinical response may be achieved in 
ALCL patients treated with selective small-molecule ALK inhibitors, but, similarly to other types 
of “kinase addicted cancers”, some of those patients are expected to develop drug resistance. 
Therefore, the identification of NPM-ALK mutants in ALCL primary tumours may be useful and 
mandatory to the rational design of more effective inhibitors. 
The aim of this study is the ultra-deep mutational analysis of NPM-ALK kinase domain in a 
cohort of pediatric patients before the onset of treatment and the functional characterization 
of mutations identified, both in terms of oncogenic activity and sensitivity to ALK-specific 
inhibition. 
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3. MATERIALS AND METHODS 
 
3.1 PATIENTS, SAMPLES AND CELL LINES 
 
A total of 37 tissue samples from ALK-positive ALCL patients enrolled between 
December 2000 and September 2010 in BFM-based AIEOP treatments protocols were 
included, after obtaining institutional board approval. Diagnosis was reviewed by the 
AIEOP (Associazione Italiana di Ematologia ed Oncologia Pediatrica) central panel of 
pathologist in all of the cases, and further characterized in our laboratory by means of 
RT-PCR using primers specific for t(2;5)(p23;q35) translocation. Reversed-transcribed 
RNA from a neuroblastoma patient carrying the R1275Q mutation was used as positive 
control (a kind gift of Dr. Luca Longo and Dr. Gian Paolo Tonini, Italian Neuroblastoma 
Foundation, Genova), while cDNA from human, non-pathologic brain tissue was included 
as negative control for amplicon library preparation and sequencing. 
With respect to cell lines, neuroblastoma cells SK-N-SH, carrying the F1174L mutation, 
and monkey renal epitelian COS7 cells were grown in RPMI 1640 medium supplemented 
with 10% fetal calf serum (FCS) (Gibco, Life Technologies Co., Carlsbad, CA, USA),    
t(2;5)-positive ALCL Karpas299 cells were grown in 15% FCS RPMI 1640 medium, and the 
human embryonic kidney HEK-239T cells in DMEM medium enriched with 10% FCS. All 
culture media were supplemented with 2 mM glutamine (Gibco, Life Technologies Co., 
Carlsbad, CA, USA), 100U/ml penicillin and 100 µg/ml streptomycin (SIGMA-Aldrich Co., 
St. Louis, MO, USA) 
 
3.2 REAGENTS AND ANTIBODIES 
 
The dual ALK and c-MET inhibitor PF-02341066 (Crizotinib) was purchased from 
Selleckchem (Selleck Chemicals, Houston, TX, USA), dissolved in DMSO and stored at  
-20°C. Antibodies were purchased from Cell Signaling (anti-Phospho-STAT3Y705, anti-
Phospho-ERK1/2T202/Y204, anti-Phospho-ALKY1604, anti-Phospho-ALKY1278/Y1282/Y1283, rabbit 
anti-myc) (Cell Signaling Technology, Inc., Danvers, MA, USA); Santa Cruz (anti-STAT3, 
anti-ERK1/2) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA); Invitrogen (rabbit 
anti-ALK, anti-V5, mouse anti-myc) (Invitrogen, Life Technologies Co., Carlsbad, CA, 
USA); SIGMA-Aldrich (anti-β-tubulin) (SIGMA-Aldrich Co., St. Louis, MO, USA). DAPI 
nucleic acid stain, and fluorophore-conjugated goat anti-rabbit Alexa488 and goat anti-
mouse Alexa546 antibodies were bought from Molecular Probes (Molecular Probes,  Life 
Technologies Co., Carlsbad, CA, USA). Horseradish peroxidase-conjugated sheep anti-
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mouse, donkey anti-rabbit antibodies and protein G-sepharose Fast-FlowTM beads were 
purchased from GE Healthcare (GE Healthcare Life Sciences, Uppsala, Sweden). The BCA 
protein assay was from Pierce (Thermo Fisher Scientific, Inc., Waltham, MA, USA) while 
Western blot chemiluminescence reagents were purchased from PerkinElmer 
(PerkinElmer Inc., Waltham, MA, USA). Films were purchased from GE Healthcare, while 
nitrocellulose membranes were from Whatman (Whatman, GE Healthcare Life Sciences, 
Uppsala, Sweden). All other reagents, if not specified, were purchased from SIGMA-
Aldrich. 
 
3.3 STATISTICAL ANALYSIS 
 
Survival analysis was performed according to Kaplan–Meier method. The 5-years overall 
survival (OS) was calculated from the date of diagnosis to the date of death from any 
cause or to the date of last follow-up. The 5-years progression-free survival (PFS) was 
calculated from the date of diagnosis to the date of the first event (tumor progression or 
relapse) or to the date of last follow-up. P-values are two-sided, with a type I error rate 
fixed at 0.05. Statistical analysis was performed by using the SAS statistical program 
(SAS-PC, version 9.3; SAS Institute Inc., Cary, NC, USA). 
 
3.4 RT-PCR AND AMPLICON LIBRARY PREPARATION 
 
Total RNA was isolated using TRIzol reagent (Invitrogen, Life Technologies Co., Carlsbad, 
CA, USA), following the manufacturer's instructions. An amount of 1 µg of total RNA was 
reverse transcribed using SuperScript II reverse transcriptase (Invitrogen, Life 
Technologies Co., Carlsbad, CA, USA) and random hexamers. Briefly, samples were 
denatured at 75°C for 3 min and cooled in ice for 5 min. Subsequently, 10 µl of reaction 
mixture were added, containg 1X buffer, 2 mM of each dNTP (GE Healthcare Life 
Sciences, Uppsala, Sweden), 250 nM random hexamers and 40 U of RNAse inhibitor 
(Roche Applied Science, Penzberg, Germany). After 10 min at 20°C, 10 mM DDT and  
200 U of SuperScript II reverse transcriptase were added. Retrotranscription was 
performed as follows:  60 min at 37°C, 5 min at 99°C, 5 min at 4°C. ALK KD coding region, 
corresponding to ALK exons 22-25, was amplified using special fusion primers, consisting 
in a 18-19 nt target-specific sequence on the 3’-end and a 19 nt fixed sequence on the 
5’-end (adapter A on forward primer and adapter B on reverse primer), according to 
manufacturer’s guidelines. A tag sequence (Multiplex Identifier, MID) of 10 nt specific 
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for each primer pair was added between the adapter and template specific sequences, 
to allow pooling of 22 different samples in the same sequencing run (Figure 5). Primer 
sequences are reported in Table 1. Each reaction mixture contained 1 µl of cDNA, 1X 
Buffer, 1.5 mM MgCl2, 200 µM of each dNTP, 200 nM of each primer and 1 U of Taq 
Gold (Applied Biosystems, Life Technologies Co., Carlsbad, CA, USA), in a final volume of 
50 µl. PCR reaction consisted of initial denaturation at 95°C for 7 min, followed by 10 
cycles of 94°C for 15 s, 65°C for 15 s, 72°C for 1 min,  25 cycles of 94°C for 15 s, 60°C for 
15 s, 72°C for 1 min, and a final extension at 72°C for 10 min. Negative and positive 
controls used were a commercially available human brain cDNA library (Human MTC 
Panel I, Clontech Laboratories Inc., Mountain View, CA, USA) and Karpas299, SK-N-SH 
and a neuroblastoma tissue sample, respectively. PCR products were analyzed by 2% 
agarose gel electrophoresis and visualized under UV trans-illumination by SYBR® Safe 
staining (Invitrogen, Life Technologies Co., Carlsbad, CA, USA), using MassRulerTM Low 
Range DNA ladder (Thermo Fisher Scientific Inc., Waltham, MA, USA) as molecular 
weight standard. Amplicon products were, thus, quantified using the Quantity One 
software (Bio-Rad Laboratories Inc., Hercules, CA, USA) and pooled at an equimolar 
ratio. To remove excess of primers and other reaction components, the amplicon pool 
was run on agarose gel, and the sample band, after being excised, was purified using the 
QIAquick gel extraction kit (Qiagen Co., Hilden, Germany). Finally, the sample was 
diluted to a final concentration of 107 PCR fragment molecules/µl. 
 
 
 
Figure 5 Schematic representation of fusion primers for the amplification and sequencing of ALK 
kinase domain. 
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3.5 NEXT-GENERATION ULTRA-DEEP SEQUENCING 
 
Amplicon ultra-deep sequencing was performed at BMR Genomics (Padova, Italy), using 
the Roche Genome Sequencer (GS) FLX 454 (Roche Applied Science, Penzberg, 
Germany). The samples were analyzed in two separate runs of 22 amplicons each, using 
1/8 lane of the GS FLX PicoTiterPlate. The amplicon-PCR-derived fragments were 
annealed to carrier beads and clonally amplified by emulsion PCR (emPCR),  according to 
the manufacturer’s protocol.  Briefly, the beads were isolated and compartmentalized 
into droplets of an aqueous PCR reaction buffer in oil emulsion. Subsequently, the 
emulsions were broken by isopropanol to facilitate collection of the amplified fragments 
bound to their specific beads. The beads carrying single-stranded DNA templates were 
enriched, counted and deposited into the PicoTiterPlate for sequencing. A CCD camera-
based imaging assembly was used to capture the pyrosequencing-derived light signal. A 
nucleotide sequence output read (“flowgram”) was generated by integrating the light 
signal for each flown nucleotide and correlating the measured signal to dynamically 
determined thresholds for mono- and multi-mers of each nucleotide. 
 
3.6 DATA ANALYSIS AND DETECTION OF VARIANTS 
 
All data were generated using the GS Sequencer software version 2.5.3 (Roche Applied 
Science). Image processing and amplicon pipeline analysis was performed using default 
settings of the GS RunBrowser software version 2.5.3 (Roche Applied Science). Sequence 
alignments and variant detection was performed using the GS Amplicon Variant 
Analyzer (AVA) version 2.7 (Roche Applied Science), in combination with a blast-based 
pipeline for low frequent large insertions/deletions (INDELs) (CRIBI Genomics, University 
of Padova, Padova, Italy). AVA software filters were set to display sequence variances 
represented even by a single read. 
The Human nucleophosmin-anaplastic lymphoma kinase fusion protein mRNA sequence 
(GenBank U04946) was used as reference sequence. Point mutations (single nucleotide 
polymorphisms, SNPs) were considered when present with a frequency of at least 0.5% 
in both forward and reverse reads, while INDELs were considered when validated by 
both software, regardless of frequency. To confirm calls made by both software, 
consensus alignments and individual flowgrams were manually reviewed. 
INDEL consensus sequences were analyzed using the mRNA-to-genomic alignment 
program Spidey (http://www.ncbi.nlm.nih.gov/spidey). 
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3.7 HOMOLOGY MODELLING AND MOLECULAR DYNAMICS SIMULATION 
 
ALK mutants were analysed through the MOE Protein Align tool, which is a modified 
version of the Needleman methodology. In this approach, substitution matrix (BLOSUM 
62 in our case) are applied to pairs of aligned residues to produce residue similarity 
scores used to optimize sequence alignments;  gap penalties of one sequence in respect 
to the other are also taken into consideration. The homology models of R308Ins8 and 
R308Ins12 were obtained through the MOE homology modeling tool, a method used  to 
build and refine 3D models for protein sequences, based on homologous template 
protein structures. The two sequences were aligned as described before to the 
crystallographic template of human ALK (PDB code: 3LCT). The models have been 
generated using AMBER99 forcefield, in the presence of the ADP docked to the template 
active site. For each model a small database of intermediate models has been created; 
the final models were chosen through energetic parameters (GB/VI and Contact Energy) 
and minimized only to relieve steric strain (Medium Minimization).  
The protonation state of the two ALK R308Ins8 and R308Ins12 tyrosine kinase models 
were evaluated with Protonate3D (T=300K pH=7) within MOE and Protonate within 
AmberTools 1.5.  Subsequently, we used tLeap and Amber FF99SB to parameterized the 
protein models. We solvated them in TIP3P water boxes and added counterions              
(Na+; Cl-) to assure the neutrality of the molecular systems. ClickMD has been used as 
molecular dynamic platform for NAMD 2.9 minimization (100000 step, conjugated-
gradient method), equilibration (0.5 ns, alpha carbon positional restrains) and 
production phase (100 ns NVT, P = 1 atm, T = 300 K) of the molecular systems through 
100000 conjugated gradients method. ACEMD v2728 has been used as molecular 
dynamics engine on nVidia GeForce GTX680 computational platform. Finally, the 
analysis of the resulting trajectories was based on RMSD overtime, RaibowRMSD, 
heatmaps and distance analysis employing VMD 1.9.1, RMSD Trajectory Tools 2.01, 
RAINBOWRMSD and NRGPLOT. 
 
3.8 SITE-DIRECTED MUTAGENESIS 
 
The pcDNA3 plasmids containg wild-type and K210A NPM-ALK has been previously 
obtained from the original pSRα-tkneo-NPM-ALK plasmid (a kind gift from Dr. S. Morris, 
S. Jude Research Hospital, Memphis, TN, USA). Site-directed mutagenesis was 
performed using the Phusion site-directed mutagenesis kit (Thermo Fisher Scientific Inc., 
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Waltham, MA, USA) and the pcDNA3-NPM-ALK as a template. Deletional (Del) and 
insertional (Ins) mutants were generated using specific HPLC-purified 5’-phosphorilated 
oligonucleotides and 500 pg of template DNA, according to the manufacturer’s 
instructions. PCR cycling conditions were the following: 30 s at 98°C, followed by 25 
cycles of 10 s at 98°C, 30 s at the specific annealing temperature, 3 min at 72°C, and a 
final extension of 10 min at 72°C. Primer sequences and respective annealing 
temperatures for each INDEL mutation are listed below.  
 
Del(923-924): FW 5'P-GACATTGCTGCCAGAAACTGC-3'      55°C 
 REV 5'P-GGTGGATGAAGTGGTTTTCCTCC-3'   
  
Del(826-924): FW 5'P-TATTTGGAGGAAAACCACTTCATCCAC-3'   55°C 
 REV 5'P-CGGGCGAGGGCGGGT-3'              
   
Del(696-825): FW 5'P-AGCCAGCCCTCCTCCCTGGCC-3'        57°C 
 REV 5'P-CTGATGATCAGGGCTTCCATGAGG-3'     
  
Ins24(924): FW 5'P-CTTTCTTCCCAGAGACATTGCTGCCAGAAACTGC-3' 62°C 
 REV 5'P-GAAATGCATTTCCGGTGGATGAAGTGGTTTTCCT-3' 
  
Ins36(924): FW 5'P-CATTTCCTTTCTTCCCAGAGACATTGCTGCCAGAAACTG-3' 65°C 
 REV 5'P-CATTTCCTAATTTTATCCCGGTGGATGAAGTGGTTTTCCT-3'  
 
An amount of 2 µl of the PCR product was circularized with Quick T4 DNA Ligase, 
according to the manufacturer’s recommendations, in a final volume of 10 µl. 
Competent E. coli  DH5α cells (Invitrogen, Life Technologies Co., Carlsbad, CA, USA) were 
transformed with 2 µl of the ligation reaction product, and serial dilutions of 
transformed bacteria (200 µl, 100 µl and 50 µl) were plated on LB agar plates containing 
50 µg/ml ampicillin. LB agar plates were incubated overnight at 37°C, and at least 4 
colonies for each transformation were isolated and grown overnight in LB containg  
100 µg/ml ampicillin, with constant shaking  (225 rpm). Plasmid DNA was extracted 
using the QIAprep Spin Miniprep Kit (Qiagen Co., Hilden, Germany) according to the 
manufacturer’s protocol, and stored at -20°C until used. All INDEL mutations were 
confirmed by sequencing of both strands. 
 
3.9 SUBCLONING 
 
The pBudCE4.1 expression vector (Invitrogen, Life Technologies Co., Carlsbad, CA, USA) 
was chosen to express simultaneously wild-type and mutated NPM-ALK. Wild-type (WT) 
NPM-ALK was subcloned into the EF-1α multiple cloning site (MCS) and fused to the V5 
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epitope, while NPM-ALK mutants were subcloned into the CMV MCS and fused to myc 
tag (Figure 6). However, to do that, a silent point mutation was introduced at nucleotide 
1887 (GTA → GTT) of wild-type NPM-ALK to remove an internal KpnI restriction site 
(GGTACC) and allow subcloning into pBudCE4.1 expression vector, using 700 pg of 
template DNA and the Phusion site-directed mutagenesis kit. Oligonucleotides were the 
following: FW 5'P-CAATATGAAGGAGGTTCCTCTGTTCAGGC-3'; REV 5'P-
GCAGTCAGCGAAGAGGGCTCTA-3'. Amplification reaction was performed as described 
previously, with an annealing temperature of 69°C. In addition, stop codons and 
untranslated sequences of out-of-frame (OOF) deletional mutants were removed before 
cloning into pBudCE4.1 plasmid, using the same mutagenesis approach. A common 
forward primer was used (5'P-ATCGATACCGTCGACCTCGAG-3'), whereas 3 different 
reverse primers were designed (5'P-GGGCCCAGGCTGGTTCATGCT-3' for WT, Del(826-
924) and Ins24(924); 5'P-TAGTAGCTCGCCCTGTAGATGTCTCG-3' for Del(923-924); 5'P-
AGAGGCAGTTTCTGGCAGCAAT-3' for Del(696-825)) in the same amplification conditions: 
30 s at 98°C, 25 cycles of 10 s at 98°C, 30 s at 68°C, 3 min at 72°C, and a final extension 
of 10 min at 72°C. Ligation, transformation and plasmid preparation were performed as 
indicated in paragraph 3.7. All mutations were confirmed by bidirectional sequencing. 
Briefly, digestion was performed using 2 µg each of pcDNA3-WT and pBudCE4.1 
expression vectors, 20 U of  KpnI and 40 U of XhoI (New England Biolab Inc., Ipswich, 
MA, USA), in a final volume of 20 µl. Linearized pBudCE4.1 was directly purified with the 
QIAquick PCR purification kit (Qiagen Co., Hilden, Germany) and eluted in 50 µl of TE 
buffer, whereas digested pcDNA3-WT was loaded in a 2% agarose gel, the insert band 
excised, purified with the QIAquick Gel extraction kit and then recovered with 30 µl of 
TE buffer. The ligation reaction contained 1X buffer, 2 µl of T4 DNA ligase (New England 
Biolabs Inc., Ipswich, MA, USA) and a molar ratio of 1:3 of insert to vector, in a final 
volume of 20 µl. Samples were incubated overnight at 16°C and used to transform 
competent E. coli  DH5α, following the manufacturer’s protocol. An amount of 200 µl, 
100 µl and 50 µl of each transformation were plated on Low Salt LB agar plates 
containing 25 µg/ml zeocin (Invitrogen, Life Technologies Co., Carlsbad, CA, USA) and 
incubated overnight at 37°C. At least 4 colonies for each transformation were isolated 
and grown overnight in Low Salt LB medium supplemented with zeocin (25 µg/ml) and 
under constant shaking (225 rpm). Correct insertions were verified by restriction enzyme 
digestion with KpnI and XhoI. 
An additional step of site-directed mutagenesis was performed on pBudCE4.1/WT to 
establish the correct reading-frame between NPM-ALK and the V5 tag. PCR amplification 
MATERIALS AND METHODS 
 
22
was done as previously described, using specific primers (FW 5'P-
CCGTCGACCTCGAGAGATCTG-3'; REV 5'P-GGGCCCAGGCTGGTTCATGCT-3') and an 
annealing temperature of 69°C. 
The mutated NPM-ALK inserts were excised with 20 U of HindIII and 20 U of XbaI (New 
England Biolab Inc., Ipswich, MA, USA) and the insert bands purified from agarose gel as 
previously indicated. Empty pBudCE4.1 and pBudCE4.1/WT were digested and linearized 
as reported above. Each mutated insert was ligated into both plasmids, following the 
same ligation and transformation protocol as for WT, and validated by restriction 
enzyme digestion with XbaI and HindIII. 
 
 
Figure 6 Map of the expression vectors pcDNA3 and pBudCE4.1.  
Restriction sites for wild-type insert are indicated with open arrowheads, restriction sites for 
mutated inserts with closed arrowheads. 
 
 
3.10 TRANSIENT TRANSFECTION AND TREATMENTS 
 
To evaluate the effects of NPM-ALK INDEL mutations generated, HEK-239T cells were 
transiently transfected with wild-type NPM-ALK and/or INDEL mutants. Three days 
before transfection, 0.8 x 106 cells were plated in 100 mm petri dishes and let grown 
under standard cell culture conditions. Exponentially growing cells were then 
transfected with 20 µg of each plasmid and 50 µl of LipofectamineTM 2000 (Invitrogen, 
Life Technologies Co., Carlsbad, CA, USA) following the manufacturer’s instructions, 
before lysis and protein detection. NPM-ALK expression and activity was analyzed in the 
presence or absence of the ALK-specific inhibitor crizotinib, in a time- (0, 30 min, 1, 2, 4 
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and 6 h) and dose- (0.5, 1.0, 5.0 µM) dependent manner. To assess localization of wild-
type and mutant NPM-ALK proteins, COS7 cells (0.2 x 105) were plated on 8-well 
chamber slides, transfected with 0.5 µg of the above reported plasmids plus 1.25 µl of 
LipofectamineTM 2000 and processed for immuoflorescence. 
 
3.11 CELL LYSIS, IMMUNOBLOTTING AND IMMUNOPRECIPITATION  
 
The cells were washed twice in ice-cold 1X phosphate-buffered saline (PBS) and lysed by 
addition of TritonX-100 sample buffer (10 mM Tris-HCl [pH 7.5]; 130 mM NaCl; 1% 
TritonX-100; 5 mM EDTA; 1 mg/ml BSA; 20 mM sodium phosphate [pH 7.5]; 10 mM 
sodium pyrophosphate [pH 7.0]; 25 mM glycerophosphate; 1 mM sodium 
orthovanadate; 10 mM sodium molybdate; 1 mM PMSF; 20 μg/ml leupeptin; 20 μg/ml 
aprotinin). Cell lysates were clarified by centrifugation (at 4°C) at 14000 × g for 30 min 
and protein concentrations were determined by the BCA assay using BSA as a standard. 
Binding of wild-type NPM-ALK to each mutant was performed by incubating protein 
extracts with 1–2 μg of specific antibodies (anti-V5, anti-myc and anti-Phospho-ALK) at 
4°C overnight. Immunocomplexes were adsorbed to 20 μl of Protein G-Sepharose beads 
for 2 h at 4°C. The immunoadsorbed pellets were washed 4 times with 1% Triton X-100 
lysis buffer and heated at 95°C in 1X reducing Laemmli loading buffer. Aliquots of cell 
lysates (50 µg) and immunoprecipitates were diluted in 5X reducing Laemmli loading 
buffer [2% SDS, 100 mM DTT, 60 mM Tris (pH 6.8), 0.01% bromophenyl blue, and 10% 
glycerol], fractionated by 10% SDS-PAGE and electrotransferred to nitrocellulose 
membranes. Proteins were visualized by chemiluminescence. Films were scanned and 
analyzed by using image analysis software (NIH Image, National Institute of Health, 
Bethesda, MD, USA) 
 
3.12 IMMUNOFLUORESCENCE 
 
Transfected HEK-293T cells were fixed in 3.7% paraformaldehyde, permeabilized in 0.2% 
TritonX-100 and blocked in 100 mM glycin, followed by incubation in 10% FCS-PBS. 
Permeabilized cells were incubated for 1 h at 37°C with the specific primary antibodies 
(mouse anti-V5 and rabbit anti-myc) and, washed in PBS, incubated with fluorophore-
conjugated secondary goat anti-rabbit Alexa488 and goat anti-mouse Alexa546 
antibodies, at a 1:1000 dilution of 2 mg/ml stock. Cells were then washed in PBS, 
mounted onto slides with 1:1 PBS/glycerol, with the addition of DAPI nucleic acid stain 
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(1:1000). The cells were observed at 63X/0.75 NA in a Leica DMBL microscope. Images 
were acquired with a Leica DC 300F digital camera and prepared for reproduction with 
Leica IM1000 software (Leica Mycrosystem Ltd., Germany). 
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4. RESULTS 
 
4.1 IDENTIFICATION OF NPM-ALK KD MUTATIONS  
 
To detect somatic tumour mutations that may predict treatment response in ALK-
positive ALCL patients, ALK kinase domain mutational status was investigated in 37 
tumour specimens by 454 amplicon ultra-deep sequencing, using a healthy human brain 
cDNA library and neuroblastoma tumour cells as negative and positive controls, 
respectively. About 99,000 sequences aligned with ALK exons 22-25 were obtained 
(mean of 2,234 ± 734 sequences per sample) and an overall of 686 sequence variants 
were detected (300 SNPs and 386 INDELs). To ensure maximum detection sensitivity, 
filters were set to display sequence variances represented even by a single read. 
However, to discard false positive variants, SNPs consensus alignments and individual 
flowgrams were manually inspected for proper variant calling and validated if 
represented with the same frequency (≥0.5%) on both forward and reverse reads, 
whereas INDELS were considered if validated by at least two independent alignment 
algorithms. In this context, a total of 7 SNPs were confirmed, 5 of which represented 
silent point mutations, while two were missense mutations at R1275 and R1231 
positions in patients 17 and 36, respectively (Figure 7A and B). As expected, ALK point 
mutations were found in neuroblastoma tumour cells (ALK F1174L in SK-N-SH NB cell 
line, and ALK R1275Q in a NB tumour sample) but not in the healthy human brain cDNA 
library.  
Since most of dedicated programs are able to rapidly analyze all the reads reporting 
SNPs and small INDELs, but they often fail to manage large insertions/deletions, we 
validated INDELs by combining Roche AVA software and a high sensitive blast-based 
pipeline developed by CRIBI Genomics. In this respect, among the 386 INDELs detected 
by Roche AVA software, 65 were large gaps, including 9 deletions and 3 insertions that 
were detected by the CRIBI Genomics pipeline as well. Of these 12 INDELS, a deletion of 
130 nt corresponding to the entire ALK exon 23, Del(696-825), was found in all patients 
with a frequency ranging from 1 to 12.8%, while the remaining 11 were expressed in a 
variable number of patients at low frequency (~0.5%) (Table 2). Of note, a common 
INDEL, previously reported in neuroblastoma tumor cells [71], (Del(923-924), freq. 1.4-
4%), was detected by Roche AVA software only. However, further sequencing analysis 
demonstrated that this deletion was present in the healthy human brain cDNA library as 
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well (13.9 %), supporting the hypothesis of a potential splicing error rather than a novel 
somatic variant in ALCL transformed cells. Indeed, to determine if INDEL mutations 
detected could represent NPM-ALK alternative spliced transcripts, each consensus was 
aligned to the respective genomic sequence using the mRNA-to-genomic alignment 
program Spidey, and in 9 of 13 variants, including Del(923-924), canonical splicing sites 
were identified at the boundaries of deleted or inserted regions. In 5 of these, the 
mutation resulted in out of frame (OOF) transcript products, corresponding to truncated 
proteins. 
 
4.2 MOLECULAR MODELLING ANALYSIS OF NPM-ALK INDEL MUTATIONS  
 
To investigate the effect of INDEL mutations detected in vivo on the structure and 
activity of NPM-ALK, molecular homology modelling analysis was performed. In 10 of 13 
variants, the mutations were most likely disruptive of protein function, being associated 
to extensive protein truncation or deletion of crucial regions of the kinase domain, while 
in 3 variants the structural rearrangements were compatible with ALK enzymatic 
activity. Therefore, we decided to concentrate our studies on the two deletions that 
were most common in our patients (Del(923-924) and Del(696-825)) and on the 3 in 
frame mutations that conserved most of the residues and motifs critical for ATP-binding 
and hydrolysis (Del(826-924), Ins24(924) and Ins36(924)). As for the common deletions, 
Del(923-924) caused a translational frame shift at the catalytic Asp309 (D309H) and 
originated an inactive protein of 342 aa (D309H-OOF) (Figure 8 and 9A), while Del(696-
825) resulted in a truncated protein of 273 aa (S232R-OOF) which presented an 
extensive deletion in correspondence of both the activation and the catalytic loops 
(Figure 9B). In addition, the DFG motif, a catalytic site responsible for the activation of 
the ALK kinase, was replaced or lost  in the two D309H-OOF and S232R-OOF NPM-ALK 
mutants, respectively, as the 3 major autophosphorylation sites (Tyr338, Tyr342 and 
Tyr343) were not conserved. In contrast, Del(826-924), Ins24(924) and Ins36(924), were 
characterized by more restrained structural modifications, which were predicted to 
maintain ALK kinase activity. In particular, Del(826-924) corresponded to an internal 
deletion of 23 aa, which, though relevant for the proper kinase conformation, did not 
affect adjacent regions participating in catalytic processes,  (Figure 9C), while Ins24(924) 
and Ins36(924) corresponded to the addition of 8 or 12 aa between Arg308 and Asp309, 
respectively (R308Ins8/12, Figure 8 and 9D). These two insertions occur within the 
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activation loop, but maintained the catalytic residues (Asp309) and motifs (glycin-rich 
and activation loop) that are important for ensure ALK active conformation. 
 
4.3 IN VITRO EXPRESSION AND ACTIVITY OF NPM-ALK INDEL MUTANTS  
 
To confirm molecular modelling analysis and to test the effects of the mutations on 
NPM-ALK kinase activity, we introduced either insertions (D309Ins8, D309Ins12) or 
deletions (∆276-299) into NPM-ALK cDNA and expressed the mutant proteins in  
HEK-293T cells. Mutated constructs were generated by site-directed mutagenesis on 
pcDNA3-NPM-ALK and used to transfect exponentially growing cells. NPM-ALK mutants 
were therefore assessed for protein expression and activity, and compared to both  
wild-type and kinase-dead NPM-ALK (NPM-ALK WT and K210A, respectively) (Figure 10). 
Notably, although both insertion and deletion mutants were effectively expressed, none 
of these showed detectable levels of phosphorylation (p-NPM-ALK) or were capable of 
signalling through the activation of downstream STAT3 and ERK1/2 effector proteins 
(Figure 10, p-STAT3 and p-ERK1/2), demonstrating that even the most conservative 
INDEL mutations were kinase inactive. These results were unexpected, particularly for 
insertional mutations, which were shown to be structurally well tolerated. Thus, to 
provide a molecular explanation to these findings, we performed molecular dynamics 
simulation on R308Ins8 and R308Ins12 NPM-ALK mutants, and compared results with 
the native ALK kinase. Insights from kinase domain modelling were generated by 
comparing time-dependent conformational changes of ALK kinase core (β-sheet; α-helix; 
hinge region; ATP-binding site) and catalytic sites (Glycin-rich ATP-binding loop, or  
P-loop; Activation loop, or A-loop; DFG motif) during protein folding. While wild-type  
P-loop showed several conformational changes during the selected time frame (Figure 
11A), R308Ins8 exhibited a different profile, with an A-loop conformational change 
simultaneous to the “Ins8” rearrangement (Figure 11B). A novel polar interaction 
between R316 of the inserted sequence (Ins8) and D338 (DFG motif) of the ALK catalytic 
loop was described (Figure 11D), and an inhibitory influence on the whole catalytic 
process was proposed. As for R308Ins12, the largest conformational changes during ALK 
“Ins12” MD simulation were in the P-loop and in the “Ins12” moieties (Figure 11C). Two 
novel interactions that “lock” the P-loop and make more difficult the entrance of the 
ATP were demonstrated, the formation of a salt-bridge interaction between D220  
(αC-helix) and K313 (“Ins12”), and a H-bond between the backbone of A186 (P-loop) and 
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the backbone of K313 (Figure 11E), suggesting that retention of intron sequences as a 
result of splicing errors may have negative effects on ALK kinase activity as much as 
skipping of exons or part of them.    
 
4.4 COESPRESSION OF NATIVE NPM-ALK AND INDEL MUTANTS  
 
In cells coexpressing native and catalytically inactive mutant NPM-ALK, the formation of 
heterocomplexes may have an impact on oncogene transforming activity, as well as on 
the sensitivity of NPM-ALK to specific inhibition. To functionally test this hypotesis, we 
coexpressed wild-type and the inactive mutants previously described:  D309H-OOF and 
S232R-OOF truncated proteins, ∆276-299 and R308Ins8 in frame INDELs. 
To ensure the same expression efficiency, we subcloned wild-type NPM-ALK and each 
mutant protein into the same pBudCE4.1 expression vector, which contains two 
promoters for high-level, constitutive, independent protein expression and a C-terminal 
tag peptides (myc or V5 epitopes) for protein detection and purification in single cells 
(Figure 12A). We performed immunoflorescence microscopy analysis to assess native 
and mutant NPM-ALK localization, which confirmed that in trasfecfected cells wild-type 
and mutant NPM-ALK proteins colocalize (Figure 12B). With coexpression, a kinase 
inactive mutant may exhibit a dominant-negative effect on the active allele, or may 
interfere with protein’s sensitivity to drug-induced inhibition. Therefore, mutant  
NPM-ALK constructs were expressed alone in HEK-293T cells, and protein steady-state 
was assessed in the presence or absence of active NPM-ALK kinase (Figure 13). As 
shown in figure, myc-tagged INDELs were expressed in HEK-293T cells independently of 
NPM-ALK expression (Figure 13A, arrowheads), and differences between mutants were 
mostly related to the severity of the modifications carried. A lower expression efficiency 
was indeed observed for both  D309H-OOF and S232R-OOF mutants compared to  
∆276-299 and R308Ins8, which were detected at higher levels either alone or in 
combination with wild-type NPM-ALK (Figure 13A, left panel). Truncated protein  
S232R-OOF, which lacks almost entirely the tyrosine kinase domain, was even barely 
detectable when expressed alone, while it was evident when coexpressed with 
constitutively active NPM-ALK (Figure 13A, right panel, samples 11 and 17, respectively). 
Notably, the mutants did not shown detectable tyrosine phosphorylation both when 
expressed alone or in combination with wild-type NPM-ALK, but exerted a dominant-
negative effect with respect to wild-type NPM-ALK autophosphorylation (Figure 13B, 
right panel, α-pALK). This did not perturb protein steady-state (Figure 13B, left panel,  
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α-V5), but significantly affected NPM-ALK signalling (p-STAT3) in transfected HEK-293T 
cells (Figure 13C, right panel). 
To test whether the reduction of NPM-ALK activity was due to the formation of inactive 
WT/INDEL heterocomplexes, fresh cell lysates were immunoprecipitated using anti-V5 
and -myc antibodies, and reciprocal immunoblottings were performed. As expected, 
myc-tagged NPM-ALK mutants coprecipitated with V5-tagged native NPM-ALK (Figure 
14A, left panel, arrowheads), likewise wild-type NPM-ALK bound to myc-tagged INDELS 
(Fig.14A, right panel, arrowhead). However, when a site-specific anti-phosphoALK 
antibody was used, we found that purified immunocomplexes contained only V5-tagged 
wild-type NPM-ALK proteins and not myc-tagged INDELs (Figure 14B, right and left 
panel, respectively). Besides, higher levels of phosphorylated NPM-ALK was found in 
cells expressing only the native protein (Figure 14B, lower panel, samples 13-18), 
indicating that there was a dominant-negative effect of INDEL mutants coexpression 
with respect to NPM-ALK activation and function. 
Finally, to investigate whether NPM-ALK mutant proteins may affect NPM-ALK sensitivity 
to inhibition (Figure 15A), HEK-293T cells expressing wild-type NPM-ALK, either alone or 
in combination with NPM-ALK INDELs, were exposed to increasing concentrations of the 
ALK-specific inhibitor crizotinib (0.5, 1 and 5 µM) for 6 h, and steady-state of both total 
and phosphorylated NPM-ALK was assessed (Figure 15B, NPM-ALK and p-NPM-ALK, 
respectively). Unexpectedly, immunoblotting experiments showed a significantly higher 
sensitivity of wild-type NPM-ALK to crizotinib in cells cotransfected with mutated  
NPM-ALK constructs, as coexpression led to a complete inhibition of NPM-ALK 
autophosphorilation (p-NPM-ALK) even at the lowest dose of 0.5 µM, while some  
NPM-ALK activity was still detectable in cells expressing the functional protein alone 
(Figure 15B). To further elucidate the kinetics of NPM-ALK inhibition, transfected cells 
were thus treated with crizotinib and time-dependent NPM-ALK inhibition was assessed. 
As shown in Figure 15C, a markedly reduced NPM-ALK phosphorylation was observed 
after 30’ of exposure to the inhibitor (graph). However, a progressive recovery of kinase 
activity was noticed in HEK-293T cell lysates containing WT or WT and S232R-OOF NPM-
ALK protein, providing further evidence of a stronger ALK kinase activity when NPM-ALK 
is expressed alone or together with unstable mutants (Figure 15C, immunoblotting). In 
the same experimental conditions, NPM-ALK-induced phosphorylation of STAT3 was 
also reduced by crizotinib (Figure 15D, graph and immunoblotting). However, when 
INDEL mutants were coexpressed, drug-dependent inhibition of NPM-ALK signalling was 
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more evident (50% p-STAT3 inhibition for WT; 20% for WT/mutant), most likely because 
of the less abundant formation of functional homodimers. 
 
4.5 PATIENTS CHARACTERISTICS AND PROGNOSTIC IMPACT OF INDEL MUTATIONS 
 
Survival analysis was conducted on 36 ALK-positive ALCL patients, 23 males and 13 
females, with median age at diagnosis of 9 years (range 3.6 months to 17.5 years). 
Patient 26 was affected by ALCL as a secondary lymphoma, and therefore excluded from 
the analysis. Most of the cases were common type ALCL (41%) and, based on St Jude 
classification, 92% of them were stage III-IV. The median follow-up of the patients was 
5.4 years (range 1.4-11.8). Twelve patients suffered from disease progression or relapse 
after a median time from diagnosis of 6.4 months (range 1.5-16.8 months). Four patients 
died, one due to disease progression, two from complications arising following blood 
stem cell transplantation as second line treatment, and one from septicemia. The 5-year 
PFS and OS of the whole study group were 66% (s.e. 8%) and 88% (s.e. 6%), respectively. 
Table 3 summarizes the main clinical characteristics of the study population, reporting 
the frequencies of the 2 common INDELs, Del(923-924) (median 0.71%, range 0.03-
3.97%) and Del(696-825) (median 2.35%, range 0.14-12.83%), and the absolute number 
of INDELs (median 4, range 2-8) identified in each patient. ALK mutational status was 
investigated at both diagnosis and relapse in 3 patients (19, 22 and 27). The prognostic 
impact of Del(923-924) and Del(696-825) was evaluated using the median frequency for 
clinical risk stratification. The 5-year PFS was 76% (s.e. 10%) and 56% (s.e. 12%) for 
patients with high (> 0.7%) and low (≤ 0.7%) frequency of Del(923-924), respectively (P = 
0.19, Figure 16A). As for Del(696-825), the 5-year PFS was 65% (s.e. 12%) and 66% (s.e. 
11%) for patients with high (> 2.4%) and low (≤ 2.4%) frequency of exon 23 deletion, 
respectively (P = 0.84, Figure 16B). In comparison, based on the absolute median 
number of INDELs, PFS was 74% (s.e. 9%) for patients with 4 or less INDELs and 50% (s.e. 
14%) for patients with more than 4 INDELs (P = 0.11, Figure 16C). Alternative splicing 
variants associated to non-canonical splicing sites were not included in this analysis. In 
summary, no clear relationship between presence of NPM-ALK INDELs and relapse was 
observed. However, since patients were not treated with an anti-ALK single-agent 
therapy, it remains unknown whether the propensity of ALCL cells to generate splice 
variants of the NPM-ALK gene may influence prognosis of ALCL treated with ALK 
inhibitors. 
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5. DISCUSSION 
 
Although ALK-positive ALCL have a rather benign prognosis, around 30% of patients do 
not respond or relapse after standard therapy, with a long-term survival of less than 
50% in relapsed cases. Moreover, intensive multi-agent chemotherapy is associated with 
considerable toxicity, a problem particularly relevant in pediatric patients [72-75]. 
It has been extensively demonstrated that aberrant ALK activity is one of the major 
oncogenic events non only in ALK-positive ALCL [28-31], but also in neuroblastoma, 
NSCLC and IMT bearing ALK activating mutations/rearrangements[40-48], and the 
inhibition of ALK kinase activity was proven to substantially reduce cancer cell 
proliferation and invasiveness both in vitro and in vivo[38, 50-52]. Consistently, 
successful clinical experience in NSCLC carrying the EML4-ALK rearrangement treated 
with crizotinib [53, 54] suggests that ALK-specific inhibition would be a valuable 
treatment strategy in ALK-positive ALCL, as well as in other ALK-addicted tumours. 
However, treatments failures after crizotinib therapy due to newly acquired secondary 
mutations have been reported in both NSCLC and IMT, due to selection of cancer cells 
with mutations in the catalytic kinase domain of ALK that impair drug binding affinity 
[56, 57]. Therapy resistance due to mutations was previously observed in the KD of  
Bcr-Abl, c-Kit or EGFR, in patients treated with small-molecule inhibitors [58-61, 76-79]. 
In this context, although a robust clinical response of ALCL patients to an ALK inhibitor is 
expected, some of those patients are also anticipated to develop resistance. Therefore, 
the knowledge of NPM-ALK mutational status in ALCL primary tumours may represent 
an important information to design efficacious anti-ALK inhibitors, as KD mutations 
present at low levels in treatment-naive patients may be selected as dominant 
mutations at relapse, if conferring a growth advantage to targeted therapy [62-64]. 
With the aim to discover functionally relevant NPM-ALK mutations, we performed ultra-
deep sequencing analysis on ALK exons 22-25, corresponding to the entire KD coding 
region, in 37 ALCL pediatric patients. Two point mutations were identified in two distinct 
cases: a G→A transition at nucleotide 1004 of NPM-ALK cDNA and a G→A substitution at 
nucleotide 872, which corresponded to the R1275Q and R1231Q mutations, 
respectively. R1275Q has been already reported as one of the most frequent activating 
mutations in neuroblastoma [40, 41, 43] and the molecular mechanism behind its 
constitutive activation has been recently elucidated [80]. The introduction of such an 
activating mutation into a constitutively activated kinase like NPM-ALK may not be 
DISCUSSION 
 
32
critical for both protein’s transforming activity and sensitivity to specific inhibition, as 
proven recently in neuroblastoma and EML4-ALK-positive NSCLC  [81, 82]. In contrast, 
the R1231Q amino acid substitution represents a novel ALK point mutation, which to our 
knowledge has never been reported neither in full-length ALK nor in the various 
truncated variants. This mutation is localized on the subdomain VIA of the C-terminal 
lobe, close to the A1234T mutation reported in neuroblastoma [43]. Differently from 
R1275Q and F1174L substitutions, which are associated to ligand-independent ALK 
activation and signalling, A1234T is a point mutation that, although affecting critical 
domains of ALK, is not oncogenic “per se” and needs to be validated as potential 
therapeutic target. Consistently, ALCL patients harbouring R1275Q or R1231Q point 
mutations were not characterized by worse prognosis. However, these patients were 
treated according to a standard chemotherapy regimen, and drug efficacy is expected to 
be independent from oncogenic ALK mutational status. Consequently, selection of 
cancer cells bearing these subtle point mutations can not be excluded if any ALK-specific 
therapy is used, and thus the molecular implications of both R1275Q and R1231Q point 
mutations on NPM-ALK function and sensitivity to inhibition need to be further 
investigated. 
Although our principal aim was the identification of KD mutations potentially relevant 
for acquired drug resistance, our approach of cDNA-based ultra-deep sequencing 
allowed us to obtain information on NPM-ALK alternative-splicing events as well. 
Alternative spliced transcripts have been extensively reported in patients with  
Bcr-Abl-positive chronic myeloid leukemia [83-93] and, more recently, for ALK receptor 
in neuroblastoma cells [71, 94], while NPM-ALK alternative splicing events have never 
been reported so far. We identified, for the first time, 9 NPM-ALK INDEL mutations, 
resulting from KD whole exons skipping or partial intron retention. In particular, 
Del(923-924), identified in all of the patients, was determined by the recognition of the 
first two bases of exon 25 as intron 24 acceptor splicing site. Assuming there are no 
other alterations outside the sequenced domain, this deletion resulted in a truncated 
NPM-ALK protein of 342 aa, which was shown to be catalytically inactive. Consistently, 
this deletion has been reported in a neuroblastoma patient, alongside the whole 
deletion of exon 27 [71], but any obvious correlation between the genetic aberration 
and the protein expression was not found. However, we detected Del(923-924) in a 
healthy brain tissue pool, where ALK kinase activity is thought to have a role in the 
developing central and peripheral nervous system [95]. We therefore suggest that 
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misrecognition of intron 24 acceptor splicing site may represent a frequent event, 
whose functional implications are not of significant relevance for both physiological and 
oncogenic ALK function. The second INDEL mutation reported in all the patients is a 
whole exon 23 deletion, Del(696-825) which leads to a truncated inactive protein of 273 
aa. The same deletion has been reported in neuroblastoma, both as solitary deletion or 
combined to exon 25 skipping [71]. We found that this deletion corresponded to a 
truncated protein product, S232R-OOF, that was clearly detectable when coexpressed 
with wild-type NPM-ALK, but not alone. Whether such a different behaviour may be 
related or not to protein stability it was not established, but the importance of the 
structural modifications carried supported this hypothesis. The great majority of the 
remaining variants identified were catalytically inactive as well, since extensively deleted 
or truncated. However, in 3 cases we hypothesized that some catalytic activity could be 
preserved. The first was a 69 nucleotide deletion, resulting from a splicing event in 
which nucleotides 893-894 AG were recognized as an alternative acceptor splice site. 
This mutation was associated to an in-frame translated protein (∆276-299), lacking 23 aa 
of the subdomain VIA on the C lobe. The other two were both characterized by a partial 
intron retention (24 and 36 nucleotides of intron 24, respectively), resulting in an 
insertion of 8 and 12 aa close to the catalytic Asp309. However, all these mutants were 
catalytically inactive, and the molecular mechanism leading to their inactivation was 
elucidated by molecular dynamics observations. Therefore, many different NPM-ALK 
alternative transcripts were identified, but all were associated to the loss of kinase 
activity. This is consistent with the observation that NPM-ALK INDELs have not a 
prognostic impact on ALCL patient’s risk stratification, and a correlation between the 
presence of INDELs and outcome coulc not be detected. However, it’s worth nothing 
that INDELs have a clear dominant-negative effect with respect to ALK kinase’s activity 
and drug sensitivity, as they associate and form nonfunctional complexes with their 
wild-type counterpart. This may have profound implication with respect to ALCL drug 
responsiveness, as INDELs can reduce the overall kinase activity and increase sensitivity 
to ALK specific inhibition, otherwise they might bind and prevent ATP-competitive 
molecules from inhibiting functional NPM-ALK kinase and ALCL cells growth. Indeed, 
when coexpressed with wild-type NPM-ALK, INDELs do interact with potentially active 
monomers and prevent NPM-ALK activation.  
In summary, our results demonstrate that NPM-ALK KD point mutations are extremely 
rare in newly diagnosed ALCL patients, but may become predominant if positive 
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selection of mutated cells is induced by novel ALK-targeting therapies. Similarly to Bcr–
Abl in CML, alternative splicing of NPM-ALK fusion gene represents a common event in 
ALCL, though the majority of patients are likely to express kinase dead fusion variants. 
We were unable to detect a correlation between the presence of this variants and the 
survival, however a significant impact of these mutations on ALCL growth and survival is 
likely if any ALK-specific treatment is used. Patients bearing a consistent level of inactive 
NPM-ALK are therefore expected to respond differently to ALK kinase inhibitors; 
whether such a response will be increased or decreased it remains to be elucidated. 
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TABLE 1 
 
Sequences of 22 fusion primer pairs for the ALK KD amplification. 
Target-specific sequences are represented in bold.  
 
 
KD_MID2_F 5’-CGTATCGCCTCCCTCGCGCCATCAG ACGCTCGACA CTGTGAAGACGCTGCCTG-3’ 
KD_MID2_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG ACGCTCGACA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID3_F 5’-CGTATCGCCTCCCTCGCGCCATCAG AGACGCACTC CTGTGAAGACGCTGCCTG-3’ 
KD_MID3_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG AGACGCACTC AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID4_F 5’-CGTATCGCCTCCCTCGCGCCATCAG AGCACTGTAG CTGTGAAGACGCTGCCTG-3’ 
KD_MID4_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG AGCACTGTAG AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID5_F 5’-CGTATCGCCTCCCTCGCGCCATCAG ATCAGACACG CTGTGAAGACGCTGCCTG-3’ 
KD_MID5_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG ATCAGACACG AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID11_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TGATACGTCT CTGTGAAGACGCTGCCTG-3’ 
KD_MID11_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TGATACGTCT AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID16_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TCACGTACTA CTGTGAAGACGCTGCCTG-3’ 
KD_MID16_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TCACGTACTA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID19_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TGTACTACTC CTGTGAAGACGCTGCCTG-3’ 
KD_MID19_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TGTACTACTC AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID22_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TACGAGTATG CTGTGAAGACGCTGCCTG-3’ 
KD_MID22_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TACGAGTATG AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID23_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TACTCTCGTG CTGTGAAGACGCTGCCTG-3’ 
KD_MID23_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TACTCTCGTG AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID28_F 5’-CGTATCGCCTCCCTCGCGCCATCAG ACTACTATGT CTGTGAAGACGCTGCCTG-3’ 
KD_MID28_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG ACTACTATGT AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID37_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TACACACACT CTGTGAAGACGCTGCCTG-3’ 
KD_MID37_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TACACACACT AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID40_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TACGCTGTCT CTGTGAAGACGCTGCCTG-3’ 
KD_MID40_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TACGCTGTCT AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID46_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TGACGTATGT CTGTGAAGACGCTGCCTG-3’ 
KD_MID46_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TGACGTATGT AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID47_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TGTGAGTAGT CTGTGAAGACGCTGCCTG-3’ 
KD_MID47_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TGTGAGTAGT AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID52_F 5’-CGTATCGCCTCCCTCGCGCCATCAG AGTATACATA CTGTGAAGACGCTGCCTG-3’ 
KD_MID52_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG AGTATACATA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID54_F 5’-CGTATCGCCTCCCTCGCGCCATCAG AGTGCTACGA CTGTGAAGACGCTGCCTG-3’ 
KD_MID54_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG AGTGCTACGA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID62_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TACGTCATCA CTGTGAAGACGCTGCCTG-3’ 
KD_MID62_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TACGTCATCA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID65_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TATGCTAGTA CTGTGAAGACGCTGCCTG-3’ 
KD_MID65_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TATGCTAGTA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID73_F 5’-CGTATCGCCTCCCTCGCGCCATCAG TGTCGTCGCA CTGTGAAGACGCTGCCTG-3’ 
KD_MID73_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG TGTCGTCGCA AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID74_F 5’-CGTATCGCCTCCCTCGCGCCATCAG ACACATACGC CTGTGAAGACGCTGCCTG-3’ 
KD_MID74_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG ACACATACGC AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID75_F 5’-CGTATCGCCTCCCTCGCGCCATCAG ACAGTCGTGC CTGTGAAGACGCTGCCTG-3’ 
KD_MID75_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG ACAGTCGTGC AGTAGCTCGCCCTGTAGAT-3’ 
KD_MID76_F 5’-CGTATCGCCTCCCTCGCGCCATCAG ACATGACGAC CTGTGAAGACGCTGCCTG-3’ 
KD_MID76_R 5’-CTATGCGCCTTGCCAGCCCGCTCAG ACATGACGAC AGTAGCTCGCCCTGTAGAT-3’ 
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TABLE 2 
 
INDEL mutations of NPM-ALK KD identified in 37 ALCL patients. 
 
 
 
 
Variant name indicates the position of deleted nucleotides on the reference sequence or the 
number of inserted nucleotides, following the corresponding starting nucleotide on the 
reference. Description indicates the alternative splicing mechanism associated to each variant, 
Protein change and Amino acids  indicate the corresponding protein mutation and the protein 
length, respectively. For each variant, the number of patients carrying the mutation and the 
respective ranges of frequency are indicated.  
* this variant was detected only by the AVA software 
** frequencies determined according to the AVA software 
       
 Variant name Description Protein change Amino acids  Patients Frequency 
             
        
1 Del(923-924)* exon 25 first 2 bases D309H OOF 342 37/37 (100%) 
     1.4 - 4% 
** 
    as 3' splice site          
2 Del(696-825) exon 23 skipping S232R OOF 273 37/37 (100%) 1 - 12.8% 
              
3 Del(696-923) exons 23-24 skipping ∆232-307 604 16/37 (43%) 0.04 - 0.6% 
              
4 Del(826-923) exon 24 skipping P276R OOF 310 18/37 (49%) < 0.5% 
             
5 Del(733-825) exon 23 partial deletion, ∆245-275 649 7/37 (19%) < 0.5% 
    alternative 5' splice site         
6 Del(826-894) exon 23 partial deletion ∆276-299 657 4/37 (11%) < 0.5% 
    alternative 3' splice site         
7 Ins24(924) intron 24 partial retention R308Ins8 688 10/37 (27%) < 0.5% 
    alternative 3' splice site         
8 Ins36(924) intron 24 partial retention R308Ins12 692 4/37 (11%) < 0.5% 
    alternative 3' splice site         
9 Ins106(924) intron 24 partial retention D309H OOF 312 10/37 (27%) 0.04 - 0.6% 
    alternative 3' splice site         
10 Del(727-766) exons 23 partial deletion I243W OOF 303 5/37 (14%) < 0.5% 
    non-canonical splice sites         
11 Del(765-799) exon 23 partial deletion L256P OOF 331 7/37 (19%) < 0.5% 
    non-canonical splice sites         
12 Del(751-841) exons 23-24 partial deletion ∆251-281 649 5/37 (14%) < 0.5% 
    non-canonical splice sites         
13 Del(771-854) exons 23 partial deletion ∆257-284 652 6/37 (16%) < 0.5% 
    non-canonical splice sites         
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TABLE 3 
 
Main clinical characteristics of the study population and INDEL distribution. 
  
 
 
 
 
DP = disease progression, REL = relapse. 
* Patients 19, 22 and 27 were analyzed at both diagnosis and relapse. Frequencies of Dels and 
number of INDELs at relapse are indicated between brackets. 
Patient Age 
(years)
Gender Histology Disease Stage 
(St Jude)
% reads 
Del(923-924)
% reads 
Del(696-825)
# INDELs Event F.U.
1 8,1 M Small Cell III 4,0 9,9 7 alive
2 9,9 M Common type III 0,2 2,7 4 alive
3 5,5 M Mixed with Small Cell Component III 0,8 3,6 5 alive
4 3,5 F Common Type III 1,6 6,3 6 alive
5 5,4 F ND III 0,5 1,4 3 alive
6 12,6 M Mixed with Lymphohistiocytic III 0,5 3,9 4 alive
7 0,6 M Lymphohistiocycitic IV 0,9 1,1 2 DP dead
8 2,6 F Mixed with Small Cell Component III 1,1 6,0 5 REL dead
9 10,8 M Common Type III 1,4 2,6 3 alive
10 6,8 F Common Type II 2,0 8,0 5 alive
11 6,0 F Mixed with Small Cell Component III 0,7 5,3 4 REL alive
12 10,8 F Common Type IV 3,7 2,2 3 alive
13 9,3 M Common Type III 2,3 2,5 5 alive
14 11,2 M Common Type III 0,8 8,9 4 alive
15 11,1 M Mixed III 0,7 4,8 2 alive
16 6,5 M ND III 0,3 12,8 8 alive
17 1,6 F Common Type III 0,8 1,4 3 alive
18 10,2 M Hodgkin-like III 1,4 5,8 4 alive
19* 5,6 M Lymphohistiocycitic III          0,3 (0,2)          5,1 (0,2)       3 (3) REL alive
20 11,2 F Common Type I 0,2 1,0 2 alive
21 0,3 M Large Cell III 2,1 3,1 5 REL alive
22* 1,5 M Mixed with Small Cell Component IV        0,9 (0)       3,3 (0)       4 (0) REL alive
23 1,7 M Lymphohistiocycitic III 2,0 2,8 5 REL alive
24 4,8 F Lymphohistiocycitic III 0,5 0,1 2 alive
25 11,4 M Common Type III 1,0 2,2 5 REL dead
27* 9,8 M Mixed with Lymphohistiocytic III           0,4 (1,0)           0,4 (0,6)       5 (2) REL alive
28 12,7 F Lymphohistiocycitic II 0,8 1,2 6 REL alive
29 9,2 F ND IV 0,2 0,7 3 alive
30 12,0 M Common Type III 0,3 0,3 3 alive
31 11,4 F Common Type III 0,4 0,5 4 dead
32 2,5 F ND III 0,0 0,3 3 REL alive
33 7,0 M Small Cell III 0,4 0,6 2 REL alive
34 15,6 M Common Type IV 0,6 0,4 2 alive
35 15,9 M ND III 0,2 0,6 2 alive
36 17,5 M Common Type III 0,4 1,0 2 alive
37 8,9 M Common Type III 0,2 0,6 4 alive
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Figure 7 Raw flowgrams from individual reads showing relative luminescence signal      
(y-axis) obtained with each sequentially flowed nucleotide (x-axis).  
(A) Raw flowgrams of unmutated sequence (upper panel) and showing the R1275Q 
mutation (lower panel) in patient 17. (B) Raw flowgrams of unmutated sequence (upper 
panel) and showing the R1231Q mutation (lower panel) in patient 36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Amino acid sequence alignments of NPM-ALK wild-type (black) and 4 
alternative splicing variants: R308Ins8 (red), R308Ins12 (orange), ∆276-299 (green), 
D309H OOF (blue) and S232R OOF (purple). Sequence differences caused by frame shift 
mutations are shown. Premature stop codons are indicated by asterisks. 
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Figure 9 Homology modelling structure of D309H OOF [Del(923-924)] (A), S232R OOF 
[Del(696-825)] (B), ∆276-299 [Del(826-894)] (C) and R308Ins8/12 [Ins24/36(924)] (D). 
Deleted or inserted regions are indicated in red. 
 
 
 
 
 
Figure 10 Western blot analysis of HEK-293T cells transiently transfected with wild-type 
NPM-ALK, K210A, and 3 INDEL mutants, showing the effect of R308Ins8/12 and ∆276-
299 expression on protein activation (p-NPM-ALK) and function (p-STAT3 and p-ERK1/2). 
γ-tubulin was used as loading control. 
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Figure 11 Molecular dynamics simulation of R308Ins8 and R308Ins12, in comparison to 
ALK native kinase. Panels A, B and C depict the alpha carbon RainbowRMSD of the WT, 
R308Ins8 and R308Ins12 tyrosine kinase domain, respectively, during the MD run. The 
largest conformational changes are circled with red boxes and correspond to the P-loop 
(Box 1), “Ins8” (Box 2) and to the A-loop (Box 3)  in panel B, “Ins12” (Box 1) and the  
P-loop (Box 2) in panel C. Panels D and E represent snapshots of R308Ins8 and 
R308Ins12 ALK kinase domain (green cartoon) conformation after 40 and 100 ns of 
simulation, respectively. The P-loop is colored in white, the αC-helix in red, the Ins8/12 
in blue and the A-loop in yellow. The side chains of R316, D338, A186, D220, and K313 
are represented in sticks. 
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Figure 12. Coexpression strategy for native and mutant (D309H-OOF, S232R-OOF, and 
R308-Ins8) NPM-ALK proteins HEK-293T cells. (A) Schematic representation of expressed 
fusion constructs and pBudCE4.1 plasmid. (B) Subcellular localization of wild-type (α-V5, 
Alexa488 green) and mutant (α-myc, Alexa546 red) NPM-ALK proteins in co-transfected 
HEK-293T cells, by immunofluorescence microscopy analysis. Nuclei were stained with  
4,6-diamidino-2-phenylindole (DAPI) dye (blue). 
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Figure 13. INDELs expression and activity in HEK293-T cells. (A) To measure INDELs 
protein expression in the presence (+) or absence (−) of wild-type NPM-ALK, western 
blot analysis was performed using an anti-myc specific antibody (α-myc). In addition, for 
proper visualization of mutants expression different time exposures were included 
(short exposure, samples 1-9; long exposure, samples 10-18). (C) Similarly, total and 
phosphorylated NPM-ALK expression was detected using an anti-V5-tag (α-V5) and 
phospho-ALK antibody (α-pALK), respectively, whereas NPM-ALK kinase activity was 
indirectly measured by assessing phosphorylation status of downstream STAT3 client 
protein (p-STAT3). Tubulin was included as loading control.  
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Figure 14 ALK myc-tagged INDELs bind and inactivate V5-tagged NPM-ALK kinase. (A) 
NPM-ALK WT/INDEL complex formation was determined in HEK293-T cotransfected cells 
by reciprocal co-immunoprecipitation, using anti-V5 (samples 1-6) and anti-myc 
(samples 7-12) specific antibodies. The corresponding immunocomplexes were then 
detected by Western blotting using anti-myc and anti-V5 antibodies, respectively. 
Untagged wild-type NPM-ALK (samples 1 and 7, −) was also included as a blank. The 
lower panel (samples 13-18) shows NPM-ALK expression in corresponding whole-cell 
lysates. INDELs were able to form holocomplexes with wild-type NPM-ALK. (B) Similarly, 
immunoprecipitation was performed using an anti-phopsho site-specific ALK antibody 
(α-pALK), and nitrocellulose blots were probed against myc- (samples 1-6, α-myc) or V5-
tagged (samples 7-12, α-V5) proteins. Compared to V5-tagged NPM-ALK, INDELs are 
neither phosphorylated nor associated with active NPM-ALK kinase. The lower panel  
shows phosphorylation status of NPM-ALK in HEK293-T whole cell lysates (samples 13-
18). Asterisk indicate nonspecific immunoglobulin (IgG) heavy chain.
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Figure 15 Effects of INDEL protein expression on NPM-ALK sensitivity to crizotinib. (A) 
Structure of the human ALK tyrosine kinase domain (TK) in complex with crizotinib (PDB 
code 2XP2). (B) To inhibit NPM-ALK kinase activity, HEK-293T cells were transfected with 
wild-type NPM-ALK alone (−) or in combination with D309H-OOF, ∆276-299, S232R-OOF 
and R308-Ins8 mutants, and total or phosphorylated NPM-ALK levels were measured 
after exposure to crizotinib (0.5, 1 and 5 µM) for 6 hours. Crizotinib-induced inhibition of 
NPM-ALK phosphorylation and signaling was also assessed in a time-dependent manner, 
by exposing transfected and cotransfected cells for different time intervals (0.5, 1, 2, 4 
and 6 hours). Phosphorylated proteins (C) NPM-ALK (p-NPM-ALK) and (D) STAT3 (p-
STAT3) were detected by Western blotting (right), and band densities, measured with 
dedicated image software, were expressed in graph (left) as fold control (untreated 
samples). 
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Figure 16 Five-years PFS according to the frequency of Del(923-924) (A) and Del(696-
825) (B) and the absolute number of INDELs (C). 
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